Kymera Therapeutics Inc’s recent filing unveils that its Chief Executive Officer Mainolfi Nello unloaded Company’s shares for reported $1.83 million on Oct 29 ’25. In the deal valued at $60.99 per share,30,000 shares were sold. As a result of this transaction, Mainolfi Nello now holds 660,482 shares worth roughly $42.89 million.
Then, Mainolfi Nello bought 30,000 shares, generating $1,850,400 in total proceeds.
Before that, Gollob Jared sold 59,576 shares. Kymera Therapeutics Inc shares valued at $3,659,254 were divested by the Chief Medical Officer at a price of $61.42 per share. As a result of the transaction, Gollob Jared now holds 109,992 shares, worth roughly $7.14 million.
A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who remained covering the stock and in late October has reiterated a ‘”a Buy”‘ rating for it. Mizuho began covering KYMR with “an Outperform” recommendation on October 21, 2025. H.C. Wainwright maintained its rating on September 18, 2025. It rated KYMR as “a Buy”.
Price Performance Review of KYMR
On Friday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock jump 2.06% to $64.94. Over the last five days, the stock has gained 10.71%. Kymera Therapeutics Inc shares have risen nearly 29.88% since the year began. Nevertheless, the stocks have risen 61.42% over the past one year. While a 52-week high of $65.74 was reached on 11/14/25, a 52-week low of $19.44 was recorded on 04/09/25.
Levels Of Support And Resistance For KYMR Stock
The 24-hour chart illustrates a support level at 61.90, which if violated will result in even more drops to 58.85. On the upside, there is a resistance level at 68.22. A further resistance level may holdings at 71.50.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-10-31, dropping by 39858.0 shares to a total of 8.05 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 8.09 million shares. There was a decline of -0.5%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 17, 2025 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
